Retina news: What's hot (and not)

Video
Conference|SECO

Mohammad Rafieetary, OD, FAAO, offers a sneak peek at the latest (and fake!) news in retina.

During SECO 2022, Mohammad Rafieetary, OD, FAAO, consultative optometric physician at the Charles Retina Institute in Germantown, Tennessee, offers Optometry Times®' Alex Delaney-Gesing a sneak peek at the latest news in retina— including for diabetic retinopathy and age-related macular degeneration (AMD) —as well as common "fake news" circualting in medicine as a whole.

See more conference coverage

Recent Videos
EnVision Summit Cochair Cecelia Koetting, OD, FAAO, Dipl ABO, says that attendees should get ready for more discussion-based panels at this year's conference.
Bonnie An Henderson in an interview for the EnVision Summit
EnVision Summit cofounder and program chair Dr Bonnie Henderson chats about collaborative eye care
Bonnie An Henderson in an interview for the EnVision Summit
EnVision Summit Co-chairs Sherrol Reynolds, OD, FAAO; Katie Rachon, OD, FAAO, Dipl ABO; Jessica Steen, OD, FAAO, Dipl ABO; and Cecelia Koetting, OD, FAAO, Dipl ABO; express excitement for the upcoming conference and why optometrists should attend.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Related Content
Ocugen announces 2-year safety and efficacy update for Phase 1_2 OCU400 for the treatment of RP - Image credit: Adobe Stock / ©Flashizzle_peopleimages.com

Ocugen announces 2-year safety and efficacy update for Phase 1/2 OCU400 for the treatment of RP

Sydney M Crago, Editor, Modern Retina
January 20th 2025
Article
Optometry Times You and Eye

You and Eye: What optometrists need to know about low vision

Miriam Korik, OD;Emily Kaiser Maharjan, Assistant Managing Editor
March 13th 2024
Podcast
City Therapeutics and Bausch + Lomb join forces to develop geographic atrophy candidate - Image credit: Adobe Stock / ©Stockwerk-Fotodesign

City Therapeutics and Bausch + Lomb join forces for GA treatment candidate

Sydney M Crago, Editor, Modern Retina
January 17th 2025
Article
Advances in treatment for geographic atrophy

Advances in treatment for geographic atrophy

David S. Boyer, MD;Tina Mac Donald, OD, CDCES, FAAO;Leo P. Semes, OD, FAAO
October 11th 2023
Podcast
Webinar being held on tablet Image credit: AdobeStock/AndreyPopov

The Vision Council to hold webinar on upcoming Vision Expo East 2025

Jordana Joy, Associate Editor
January 14th 2025
Article
Sleep apnea may be linked to AMD - Image credit: Adobe Stock / ©Rawpixel.com

Is there a link between sleep apnea and AMD?

Lynda Charters
January 13th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.